IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated

Journal of the Neurological Sciences

Volumn 346, Issue 1-2, 2014, Pages 116-120

  Evidente, Virgilio Gerald H ^a   Truong, Daniel ^b   Jankovic, Joseph ^c   Comella, Cynthia L ^d   Grafe, Susanne ^e   Hanschmann, Angelika ^e  

^a Movement Disorders Center of Arizona   (United States)

^b Parkinson's and Movement Disorder Institute   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Blepharospasm; Botulinum toxin; Cervical dystonia; IncobotulinumtoxinA; Patient satisfaction; Xeomin

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ARTICLE; BLEPHAROSPASM; CERVICAL DYSTONIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSPHAGIA; EXPLORATORY RESEARCH; FOCAL DYSTONIA; HUMAN; INJECTION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NECK PAIN; PATIENT SATISFACTION; POST HOC ANALYSIS; PTOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; XEROSTOMIA; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; OUTCOME ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME; TORTICOLLIS;

BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX; TIME FACTORS; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84910131709     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.08.004     Document Type: Article

References (29)

1. A. Albanese, F. Asmus, and K.P. Bhatia EFNS guidelines on diagnosis and treatment of primary dystonias Eur J Neurol 18 2011 5 18
2. M. Hallett, A. Albanese, and D. Dressler Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders Toxicon 67 2013 94 114
3. D.M. Simpson, A. Blitzer, and A. Brashear Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 70 2008 1699 1706
4. J. Frevert Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture® Drugs R D 10 2010 67 73
5. J. Jankovic, C. Comella, A. Hanschmann, and S. Grafe Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm - a randomized trial Mov Disord 26 2011 1521 1528
6. D.D. Truong, S.M. Gollomp, and J. Jankovic Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm J Neural Transm 120 2013 1345 1353
7. C.L. Comella, J. Jankovic, D.D. Truong, A. Hanschmann, S. Grafe, and U.S. XEOMIN Cervical Dystonia Study Group Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia J Neurol Sci 308 2011 103 109
8. V.G. Evidente, H.H. Fernandez, and M.S. LeDoux A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia J Neural Transm 120 2013 1699 1707
9. H.H. Fernandez, E.J. Pappert, and C.L. Comella Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naive subjects with cervical dystonia Tremor Other Hyperkinet Mov (N Y) 3 2013 [http://tremorjournal.org/article/view/140]
10. D. Dressler, S. Paus, A. Seitzinger, B. Gebhardt, and A. Kupsch Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia J Neurol Neurosurg Psychiatry 84 2013 1014 1019
11. P. Roggenkämper, W.H. Jost, K. Bihari, G. Comes, S. Grafe, and NT 201 Blepharospasm Study Team Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm J Neural Transm 113 2006 303 312
12. B. Wabbels, G. Reichel, A. Fulford-Smith, N. Wright, and P. Roggenkämper Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm J Neural Transm 118 2011 233 239
13. R. Benecke, W.H. Jost, P. Kaňovský, E. Ruzicka, G. Comes, and S. Grafe A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia Neurology 64 2005 1949 1951
14. Allergan Botox® 100 U summary of product characteristics October 2012 UK. Accessed November 15 2012, http://www.medicines.org.uk/EMC/medicine/112/SPC/
15. Ipsen Dysport® 300 U and 500 U summary of product characteristics June 2012 UK. Accessed November 15 2012, Accessed November 15 2012, http://www.medicines.org.uk/EMC/medicine/870/SPC/
16. Allergan, Inc. Botox® US prescribing information Accessed June 18 2012 http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/103000s5232lbl.pdf
17. Merz Pharmaceuticals GmbH Xeomin® US prescribing information Accessed June 19 2012 http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125360s007lbl.pdf
18. Ipsen Biopharm Ltd. Dysport® US prescribing information Accessed June 19 2012 http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125274s0052lbl.pdf
19. Merz Pharma UK XEOMIN® 100 U summary of product characteristics September 2012 UK. Accessed November 15 2012, http://www.medicines.org.uk/EMC/medicine/20666/SPC/
20. P. Greene, S. Fahn, and B. Diamond Development of resistance to botulinum toxin type A in patients with torticollis Mov Disord 9 1994 213 217
21. D. Dressler, P. Tacik, and Saberi F. Adib Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) J Neural Transm 121 2014 29 31
22. K.D. Sethi, R. Rodriguez, and B. Olayinka Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia J Med Econ 15 2012 419 423
23. D. Bensmail, and A. Hanschmann Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys of patients and physicians J Neurol Sci 333 Supplement 1 2013 e120
24. D. Swope, and R. Barbano Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia Neurol Clin 26 Suppl. 1 2008 54 65
25. J. Jankovic, K.D. Vuong, and J. Ahsan Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia Neurology 60 2003 1186 1188
26. P. Kaňovský, J. Slawek, and Z. Denes Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity Clin Neuropharmacol 32 2009 259 265
27. P. Kaňovský, J. Slawek, and Z. Denes Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity J Rehabil Med 43 2011 486 492
28. R. Mazzocchio, and M. Caleo More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system Neuroscientist 2014 10.1177/1073858414524633 [Electronic publication ahead of print, February 26, 2014]
29. R. Opavsky, P. Hlustik, P. Otruba, and P. Kaňovský Somatosensory cortical activation in cervical dystonia and its modulation with botulinum toxin: an fMRI study Int J Neurosci 122 2012 45 52